ABSTRACT
The gearbox has the advantage of being able to change the torque and rotational speed according to the gear ratio and has high power transmission efficiency by transmitting power through the contact of the gear pair. When evaluating the strength and fatigue life of a gearbox using a design load or an equivalent load, there is a possibility that the results will be very different from the actual ones. Therefore, in this study, the load duration distribution (LDD) constructed based on the actual workload was used to evaluate the strength and fatigue life of the gearbox reliably. As a result of evaluating the strength and fatigue life of the gearbox using LDD, it was confirmed that the existing gearbox did not satisfy the target lifespan in the operating environment. Therefore, the reasons for these results were analyzed, and design modification was performed based on the analyzed results. As a result of design modification, shaft deflection decreased by rearrangement of the bearings, from an overhung type to a straddle type, thereby improving the fatigue life of gears and bearings. Finally, the load distribution acting on the gear tooth surface was improved through micro-geometry modification of the gears.
Subject(s)
Fatigue , Zea mays , TorqueABSTRACT
Standards of care for elderly acute myeloid leukemia (AML) patients unfit for intensive chemotherapy remain undefined. We aimed to compare outcomes of hypomethylating agent (HMA) therapy and intensive chemotherapy (IC) in elderly AML patients and identify the subgroup of patients who are eligible for HMA therapy. We reviewed data on the outcomes of 86 AML patients aged ≥ 65 years, who had undergone treatment between 2010 and 2015. These treatments included IC (25 patients, 29.1%) or therapy using HMA including azacitidine or decitabine (61 patients, 70.9%). The overall response rates were 32 and 19.7%, respectively. Median overall survival (OS) (8 vs. 8 months) and progression-free survival (PFS) (6 vs. 7 months) durations were similar in the two groups. Patients in the HMA group with less than 10% peripheral blood (PB) blasts achieved significantly better OS duration than patients in the IC group (P = 0.043). Patients in the IC group with PB blasts and bone marrow blast of ≥ 10 and ≥ 50%, respectively, achieved better PFS durations than the corresponding patients in the HMA group (P = 0.038). Multivariate analysis identified the hematologic improvement-platelet (HI-P) as an independent prognostic factor for survival in the HMA group (P = 0.005). Our results showed that HMA therapy and IC were associated with similar survival duration in elderly AML patients. This study was noteworthy because it assessed prognostic factors that would help to select elderly patients who could expect actual benefits from undergoing the different therapeutic options available, especially HMA therapy.
Subject(s)
Antimetabolites, Antineoplastic/administration & dosage , Antineoplastic Combined Chemotherapy Protocols/administration & dosage , Clinical Decision-Making/methods , Leukemia, Myeloid, Acute/drug therapy , Leukemia, Myeloid, Acute/mortality , Aged , Aged, 80 and over , Azacitidine/administration & dosage , DNA Methylation/drug effects , DNA Methylation/physiology , Female , Humans , Leukemia, Myeloid, Acute/diagnosis , Male , Survival Rate/trends , Treatment OutcomeSubject(s)
Fusion Proteins, bcr-abl/genetics , Leukemia/diagnosis , Lymphoma, Large B-Cell, Diffuse/drug therapy , Aged , Antineoplastic Combined Chemotherapy Protocols/adverse effects , Bone Marrow Cells/cytology , Bone Marrow Cells/pathology , Female , Flow Cytometry , Granulocyte Colony-Stimulating Factor/therapeutic use , Humans , Immunophenotyping , Leukemia/etiology , Phenotype , Rituximab/administration & dosageABSTRACT
We retrospectively examined the outcomes of 56 patients with diffuse large B-cell lymphoma (DLBCL) who underwent autologous stem cell transplant (ASCT) with BEAM/BEAC (carmustine, etoposide, cytarabine, melphalan/cyclophosphamide) or busulfan (Bu)-containing conditioning regimens. The Bu group had lower disease-related mortality and more frequent achievement of complete remission (CR) after ASCT from partial remission (PR) or refractory status before ASCT compared with the BEAM/BEAC group. The estimated 2-year EFS (59.3% vs. 15.0%) and overall survival (OS) (70.2% vs. 42.0%) in pre-ASCT rituximab-exposed patients with DLBCL were higher in the Bu group. In patients with high-risk DLBCL exposed to rituximab with first remission, the Bu group had better EFS (p = 0.004) and OS (p = 0.053) rates, while survival rates for relapsed/refractory patients did not differ between groups. Bu regimens are highly effective for preparing patients with DLBCL with previous exposure to rituximab for ASCT, especially in high-risk patients who achieved a first remission.
